AB0444 Effect of rituximab on a salivary gland ultrasound score in primary sjÖgren's syndrome: results of the tractiss multicentre randomised trial sub-study

Background

B lymphocytes are important in the pathogenesis of primary Sjögren9s syndrome (PSS), but two phase III trials (TEARS and TRACTISS) of the B cell depleting agent rituximab (RTX) failed to show an effect on their primary endpoints in PSS. Whilst RTX may lack efficacy in a non-stratified PSS population, other possible explanations for these negative results include the choice and timing of primary outcome. In a small single-site...